81 related articles for article (PubMed ID: 21898320)
1. [The immune system and Alzheimer's disease].
van Exel E; Eikelenboom P; Comijs HC; Kurniawan C; Frölich M; Smit JH; Stek ML; Scheltens P; Eefsting JE; Westendorp RG
Tijdschr Psychiatr; 2011; 53(9):637-43. PubMed ID: 21898320
[TBL] [Abstract][Full Text] [Related]
2. Vascular factors and markers of inflammation in offspring with a parental history of late-onset Alzheimer disease.
van Exel E; Eikelenboom P; Comijs H; Frölich M; Smit JH; Stek ML; Scheltens P; Eefsting JE; Westendorp RG
Arch Gen Psychiatry; 2009 Nov; 66(11):1263-70. PubMed ID: 19884614
[TBL] [Abstract][Full Text] [Related]
3. Genetic risk profiles for Alzheimer's disease: integration of APOE genotype and variants that up-regulate inflammation.
Licastro F; Porcellini E; Caruso C; Lio D; Corder EH
Neurobiol Aging; 2007 Nov; 28(11):1637-43. PubMed ID: 16930778
[TBL] [Abstract][Full Text] [Related]
4. Apolipoprotein E epsilon4 allele frequency in elderly depressed patients with and without cerebrovascular disease.
Traykov L; Bayle AC; Latour F; Lenoir H; Seux ML; Hanon O; Péquignot R; Bert P; Moulin F; Cantegreil I; Wenisch E; Batouche F; Mehrabian S; Rotrou Jd; Rigaud AS
J Neurol Sci; 2007 Jun; 257(1-2):280-3. PubMed ID: 17337010
[TBL] [Abstract][Full Text] [Related]
5. APOE, vascular pathology, and the AD brain.
Yip AG; McKee AC; Green RC; Wells J; Young H; Cupples LA; Farrer LA
Neurology; 2005 Jul; 65(2):259-65. PubMed ID: 16043796
[TBL] [Abstract][Full Text] [Related]
6. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
Sunderland T; Mirza N; Putnam KT; Linker G; Bhupali D; Durham R; Soares H; Kimmel L; Friedman D; Bergeson J; Csako G; Levy JA; Bartko JJ; Cohen RM
Biol Psychiatry; 2004 Nov; 56(9):670-6. PubMed ID: 15522251
[TBL] [Abstract][Full Text] [Related]
7. Association between apolipoprotein E polymorphism and Alzheimer disease in Tehran, Iran.
Raygani AV; Zahrai M; Raygani AV; Doosti M; Javadi E; Rezaei M; Pourmotabbed T
Neurosci Lett; 2005 Feb; 375(1):1-6. PubMed ID: 15664112
[TBL] [Abstract][Full Text] [Related]
8. Increased plasma levels of soluble CD40, together with the decrease of TGF beta 1, as possible differential markers of Alzheimer disease.
Mocali A; Cedrola S; Della Malva N; Bontempelli M; Mitidieri VA; Bavazzano A; Comolli R; Paoletti F; La Porta CA
Exp Gerontol; 2004 Oct; 39(10):1555-61. PubMed ID: 15501026
[TBL] [Abstract][Full Text] [Related]
9. Insulin-like growth factor-1 and risk of late-onset Alzheimer's disease: findings from a family study.
van Exel E; Eikelenboom P; Comijs H; Deeg DJ; Stek ML; Westendorp RG
Neurobiol Aging; 2014 Mar; 35(3):725.e7-10. PubMed ID: 24054991
[TBL] [Abstract][Full Text] [Related]
10. APOE genotype, family history of dementia, and Alzheimer disease risk: a 6-year follow-up study.
Huang W; Qiu C; von Strauss E; Winblad B; Fratiglioni L
Arch Neurol; 2004 Dec; 61(12):1930-4. PubMed ID: 15596614
[TBL] [Abstract][Full Text] [Related]
11. Monocyte chemoattractant protein-1 (MCP-1) gene polymorphism and risk of Alzheimer's disease in Italians.
Pola R; Flex A; Gaetani E; Proia AS; Papaleo P; Di Giorgio A; Straface G; Pecorini G; Serricchio M; Pola P
Exp Gerontol; 2004 Aug; 39(8):1249-52. PubMed ID: 15288699
[TBL] [Abstract][Full Text] [Related]
12. D10S1423 identifies a susceptibility locus for Alzheimer's disease in a prospective, longitudinal, double-blind study of asymptomatic individuals.
Zubenko GS; Hughes HB; Stiffler JS
Mol Psychiatry; 2001 Jul; 6(4):413-9. PubMed ID: 11443525
[TBL] [Abstract][Full Text] [Related]
13. Lack of association of interleukin-1beta polymorphism with Alzheimer's disease in the Jewish population.
Rosenmann H; Meiner Z; Dresner-Pollak R; Kahana E; Aladjem Z; Grenader T; Wertman E; Abramsky O
Neurosci Lett; 2004 Jun; 363(2):131-3. PubMed ID: 15172100
[TBL] [Abstract][Full Text] [Related]
14. Middle-aged children of persons with Alzheimer's disease: APOE genotypes and cognitive function in the Wisconsin Registry for Alzheimer's Prevention.
Sager MA; Hermann B; La Rue A
J Geriatr Psychiatry Neurol; 2005 Dec; 18(4):245-9. PubMed ID: 16306248
[TBL] [Abstract][Full Text] [Related]
15. Influence of the Pro12Ala polymorphism of PPAR-gamma on age at onset and sRAGE levels in Alzheimer's disease.
Yao L; Li K; Zhang L; Yao S; Piao Z; Song L
Brain Res; 2009 Sep; 1291():133-9. PubMed ID: 19631630
[TBL] [Abstract][Full Text] [Related]
16. Nonsteroidal anti-inflammatory drug use and Alzheimer's disease risk: the MIRAGE Study.
Yip AG; Green RC; Huyck M; Cupples LA; Farrer LA;
BMC Geriatr; 2005 Jan; 5():2. PubMed ID: 15647106
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-18 promoter polymorphisms and risk of late onset Alzheimer's disease.
Yu JT; Tan L; Song JH; Sun YP; Chen W; Miao D; Tian Y
Brain Res; 2009 Feb; 1253():169-75. PubMed ID: 19073159
[TBL] [Abstract][Full Text] [Related]
18. The distribution of cerebrovascular amyloid in Alzheimer's disease varies with ApoE genotype.
Trembath D; Ervin JF; Broom L; Szymanski M; Welsh-Bohmer K; Pieper C; Hulette CM
Acta Neuropathol; 2007 Jan; 113(1):23-31. PubMed ID: 17089130
[TBL] [Abstract][Full Text] [Related]
19. Choline acetyltransferase G +4 A polymorphism confers a risk for Alzheimer's disease in concert with Apolipoprotein E epsilon4.
Kim KW; Suh YJ; Park WY; Jhoo JH; Lee DY; Youn JC; Lee KH; Seo JS; Woo JI
Neurosci Lett; 2004 Aug; 366(2):182-6. PubMed ID: 15276243
[TBL] [Abstract][Full Text] [Related]
20. Apolipoprotein E epsilon4 count affects age at onset of Alzheimer disease, but not lifetime susceptibility: The Cache County Study.
Khachaturian AS; Corcoran CD; Mayer LS; Zandi PP; Breitner JC;
Arch Gen Psychiatry; 2004 May; 61(5):518-24. PubMed ID: 15123497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
